1708574062
This Week In Medicine

Advertise on podcast: This Week In Medicine

Rating
★★★★★
5
from
2 reviews
This podcast has
271 episodes
Language
English
Publisher
A.I.O.
Explicit
No
Date created
2023/09/22
Latest episode
2026/11/16
Average duration
2 min.
Release period
3 days

Description

Welcome to This Week in Medicine - Your Filtered Medical Journal SummaryLooking to stay up-to-date with the latest medical research but short on time? This Week in Medicine has you covered!Our AI generated podcast provides you with a convenient, on-the-go solution to keep you informed about the most significant developments in the medicine field. We understand that your time is valuable, so we've done the hard work for you.Each episode offers a filtered and concentrated summary of key journal articles, allowing you to stay informed without the need to sift through pages of research papers. With This Week in Medicine, listening is faster than reading, and you can consume valuable medical knowledge while commuting, exercising, or during your daily routine. Whether you're a busy healthcare professional, a medical student, or simply someone interested in staying informed about groundbreaking medical discoveries, This Week in Medicine is your go-to resource.  Tune in to This Week in Medicine for a faster, more accessible, and engaging way to keep up with the ever-evolving world of Medicine.Subscribe now and join us on this journey to make medical knowledge accessible to everyone around the world at no cost!And always, please refer to the original article for accuracy and draw your own conclusions.

Unlock This Week In Medicine podcast Email contact info,
Listeners & Audience details

Email contact information

Direct podcast contact details

Listeners

Audience numbers & engagement insights

Audience details

Podcast Insights

Podcast episodes

Check latest episodes from This Week In Medicine podcast


NEJM November 12 2026 Prasugrel versus Ticagrelor in Acute Coronary Syndromes
2026/11/16
Medical researchers in Sweden conducted a cluster-randomized trial involving over 17,000 adults to determine whether prasugrel or ticagrelor is the superior blood-thinning medication for patients recovering from a heart procedure related to acute coronary syndromes. By shifting entire regional healthcare policies between the two drugs over a three-year period, the study tracked the one-year incidence of major ischemic events—such as repeat heart attacks, strokes, and death—alongside severe bleeding complications. The primary findings revealed no significant difference in the overall rate of ischemic events between the two treatment strategies. However, the data suggested a slightly lower occurrence of major bleeding associated with the prasugrel policy. Ultimately, the investigation concluded that utilizing prasugrel as the standard medication does not provide a reduced risk of adverse cardiovascular outcomes compared to ticagrelor.
NEJM November 12 2026 Prevention of Venous Thromboembolism after Total Hip or Knee Replacement
2026/11/16
A recent clinical trial investigated the prevention of blood clotsfollowing elective hip or knee replacement surgeries by comparing three different medications: aspirin, warfarin, and rivaroxaban. Over a thirty-day treatment period, nearly eighteen thousand patients were randomly assigned to one of these three drug regimens, with outcomes monitored for half a year. Researchers assessed both effectiveness, measured by mortality rates and symptomatic blood clots, and safety, which tracked incidents like bleeding or cardiac events. Ultimately, the trial concluded that aspirin failed to meet the noninferiority threshold compared to the two anticoagulants regarding effectiveness. Conversely, warfarin and rivaroxaban did not achieve noninferiority when compared to aspirin concerning safety outcomes.
NEJM November 12 2026 Rivaroxaban Then Aspirin vs. Aspirin Alone after Total Hip or Knee Arthroplasty
2026/11/16
A recent multicenter clinical trial investigated whether taking aspirin alone is as effective as starting with rivaroxaban before transitioning to aspirin for preventing dangerous blood clots following hip and knee replacement surgeries. Researchers randomly assigned over five thousand patients to receive either the single-drug aspirin regimen or the combined rivaroxaban-then-aspirin treatment for several days post-surgery. The primary measurements tracked the development of symptomatic venous thromboembolism alongside any potential bleeding complications over a ninety-day monitoring period. Ultimately, the data demonstrated that the aspirin-only approach successfully achieved noninferiority regarding clot prevention compared to the combined medication strategy. Furthermore, both treatment groups experienced similar rates of adverse bleeding events, suggesting that a simpler, aspirin-exclusive protocol is a viable option for joint replacement recovery.
NEJM November 5, 2026 Plozasiran for Severe Hypertriglyceridemia and Risk of Pancreatitis
2026/11/05
Recent clinical research evaluated the effectiveness of plozasiran, an innovative RNA-based therapy, in treating individuals diagnosed with severe hypertriglyceridemia. Across two closely monitored trials involving 757 participants, patients received either the targeted medication or a placebo to measure changes in fasting lipid levels over a one-year period. The findings revealed that administration of the drug resulted in dramatic triglyceride reductions compared to the control group. Furthermore, patients treated with plozasiran experienced a substantially lower incidence of acute pancreatitiswithout an increase in overall adverse events. Ultimately, the investigation demonstrates that this therapeutic approach effectively manages dangerous lipid elevations and significantly mitigates pancreatic health risks.
NEJM November 5, 2026 Targeted Use of Computed Tomographic Coronary Angiography in Acute Chest Pain
2026/11/05
A recent clinical trial investigated whether performing computed tomographic (CT) coronary angiography could lower the long-term risk of heart-related complications in emergency department patients whose heart attacks were initially excluded. Researchers across the United Kingdom monitored over 3,100 intermediate-risk participants who were randomly split to receive either specialized CT imaging or traditional medical management. Over a median tracking period of three years, the incidence of fatal cardiac events and subsequent heart attacks was evaluated. Ultimately, the findings demonstrated no significant difference in primary cardiovascular outcomes between the two approaches. Consequently, routine CT scanning did not prove superior to standard care in preventing future cardiac emergencies for this patient demographic.
NEJM November 5 , 20026 Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity
2026/11/05
A recent clinical trial investigated the effectiveness of retatrutide, an innovative triple-hormone receptor agonist, for managing obesity in adults. Over an eighty-week period, participants received weekly injections of the medication or a placebo to measure changes in body weight, knee osteoarthritis pain, and obstructive sleep apnea severity. The findings revealed that individuals treated with the drug experienced substantial weight loss compared to the placebo group. Furthermore, patients taking the medication showed notable improvements in joint discomfort and respiratory disturbances during sleep, with gastrointestinal issues noted as the most frequent side effects. Ultimately, the research concluded that this therapeutic compound offers prominent health benefits for individuals struggling with excess weight and its related complications.
JAMA October 2026 Risk-Based vs Annual Breast Cancer Screening The WISDOM Randomized Clinical Trial
2026/10/29
A large-scale clinical trial involving more than 28,000 women was conducted to evaluate whether risk-based breast cancer screening serves as a viable substitute for traditional annual mammography. By utilizing genetic testing, polygenic risk scores, and clinical models, participants in the experimental group were assigned customized screening schedules tailored to their specific vulnerability levels. The findings demonstrated that this personalized approach successfully safely stratified participants without increasing the detection of advanced-stage tumors, though it paradoxically failed to lower overall biopsy rates despite requiring fewer mammograms. Ultimately, the research highlights that while tailored screening optimizes resource allocation and matches clinical intensity to individual hazard levels, additional refinements are necessary to reduce unnecessary diagnostic procedures.
JAMA October 2026 Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer The HORIZON-Breast06 Randomized Clinical Trial
2026/10/29
The HORIZON-Breast06 clinical trial investigated the effectiveness of trastuzumab rezetecan compared to standard chemotherapy for individuals suffering from ERBB2-low advanced breast cancer. Conducted across numerous medical centers in China, the multi-center study randomly divided 551 eligible participants into two distinct treatment groups. The primary focus of the research was to measure progression-free survival rates among both chemotherapy-naive patients and the broader participant pool. Findings revealed that the novel drug substantially extended progression-free survival compared to traditional chemotherapy options, showing consistent advantages across various patient subgroups. Ultimately, the therapy established its potential as a promising alternative treatment, despite noting a higher frequency of severe adverse events primarily related to lowered neutrophil counts.
NEJM Oct 22 2026 Response-Tailored or Standard-Duration Antibiotic Treatment for Infective Endocarditis
2026/10/28
A recent international clinical trial investigated whether shortening antibiotic regimens for left-sided infective endocarditis is safe and effective once patients achieve clinical stability. Researchers compared a response-tailored strategy—which stopped antibiotics earlier—against the standard six-week duration across more than 500 participants. The findings revealed that the tailored approachsuccessfully increased the number of days patients spent free of medication without increasing major safety risks like mortality or surgery. However, this shorter treatment method carried a trade-off, resulting in a statistically higher rate of infection relapse compared to the conventional timeline. Ultimately, the study demonstrates that while individualized antibiotic duration offers greater freedom from drugs safely, clinicians must carefully weigh this benefit against the increased danger of recurrence.
NEJM Oct 22 2026 Ianalumab for the Treatment of Patients with Sjögren’s Disease
2026/10/28
Two clinical studies, NEPTUNUS-1 and NEPTUNUS-2, evaluated the effectiveness of the antibody ianalumab as a potential medical intervention for Sjögren's disease, a complicated autoimmune condition lacking specialized treatments. Researchers divided hundreds of participants into groups to compare monthly or quarterly subcutaneous injections of the medication against a placebo over the course of a year. The primary objective measured changes in disease activity scores at week 48 using standardized rheumatology indexes. Findings revealed that monthly dosesachieved a statistically significant reduction in disease severity compared to inactive treatments, despite showing no meaningful differences in specific secondary symptom evaluations. Although participants receiving the drug experienced a higher rate of mild injection-site reactions, the frequency of severe health complications remained comparable to the placebo groups.
NEJM Oct 22 2026 Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event
2026/10/28
A recent clinical trial investigated whether the medication milvexian could safely lower the chances of secondary heart attacks and strokes in individuals recovering from acute coronary syndrome. Researchers administered either milvexian or a placebo alongside standard antiplatelet treatments to over fourteen thousand participants in this global study. Ultimately, the investigation was halted early because an interim review determined the drug failed to show any benefit in preventing major cardiovascular events. Furthermore, the data revealed no significant difference in severe bleeding rates between the group receiving milvexian and those given the placebo. Scientists ultimately concluded that adding milvexian to conventional therapy does not improve protection against future ischemic incidents for these patients.
JAMA October 2026 Out-of-Pocket Costs for Chronic Illness Management in High-Deductible Health Plans
2026/10/13
A recent retrospective study examined out-of-pocket expenses for working-age adults managing common chronic conditions like diabetes and hypertension. Researchers analyzed national commercial insurance claims from 2022 to 2023 to compare financial burdens between high-deductible health plans and traditional coverage. The findings revealed that patients enrolled in high-deductible policiesfaced annual costs that were roughly 1.6 to 2.4 times greater when seeking standard, evidence-based treatments. Despite this proportional increase, the actual monetary difference remained relatively modest, ranging between roughly $64 and $86 per year. Ultimately, this research offers valuable insight into the financial challenges chronically ill patients navigate depending on their specific insurance structure.
JAMA October 2026 Patient Navigation Plus mHealth Incentives for Linkage to OUD Care for Adults Who Also Use Methamphetamines A Pilot Randomized Clinical Trial
2026/10/13
This clinical trial investigated a mobile health strategy combined with patient navigation to improve outpatient care for hospitalized adults struggling with both opioid use disorder and methamphetamine use. Researchers randomly assigned participants to receive either standard treatment or an intervention featuring financial rewards for medication adherence and dedicated support during the first month following discharge. The study successfully met its enrollment goals and demonstrated high patient satisfaction, proving that the program was both practical and well-received. Although participants in the experimental group showed slightly higher rates of connecting with outpatient care after thirty days compared to the control group, the difference was not statistically significant. Ultimately, the findings confirm that this novel approach is feasible to execute, though larger investigations are required to establish its true clinical effectiveness.
JAMA October 2026 Digital and Coaching Interventions for Uptake of Cancer Genetic Testing The MiGHT Randomized Clinical Trial
2026/10/13
The Michigan Genetic Hereditary Testing trial explored how to increase low completion rates for hereditary cancer genetic testing. Researchers evaluated nearly eight hundred adult participants who qualified for genetic evaluation across three different groups. Individuals were randomly assigned to receive either telephone-based health coaching, a self-directed digital tool, or standard care. The findings demonstrated that the digital intervention significantly improved early testing rates at six months, whereas health coaching effectively increased testing uptake over a twelve-month period. Ultimately, these alternative strategies successfully boosted testing uptake compared to standard care, highlighting the value of motivational messaging and digital delivery models in clinical care.
JAMA Cardiology October 2026 Global, Regional, and National Burden of Heart Failure, 1990-2023 A Systematic Analysis for the Global Burden of Disease Study 2023
2026/10/12
A recent cross-sectional analysis utilizing Global Burden of Disease methodologies evaluates the worldwide impact and underlying causes of heart failure across 204 countries and territories from 1990 to 2023. By synthesizing extensive data, the research revealed an estimated 56.0 million cases globally in 2023, with prevalence rates consistently rising alongside advancing age. The study highlights that specific causes vary dramatically depending on geographic region and age group, noting issues like ischemic and hypertensive heart disease in older populations alongside congenital, rheumatic, and alcohol-related conditions in younger cohorts. Because heart failure represents a growing global health challenge, targeting modifiable risk factors such as high blood pressure and excessive drinking remains crucial. Ultimately, these region-specific findings equip public health leaders with vital insights to design targeted interventions and effectively reduce disease burdens worldwide

Podcast reviews

Read This Week In Medicine podcast reviews


5 out of 5
2 reviews

Podcast sponsorship advertising

Start advertising on This Week In Medicine relevant audience podcasts


What do you want to promote?